Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04133831 · ClinicalTrials.gov registry record · NA

Don't Throw Your Heart Away: Layperson Study 1

A NA study, sponsored by Carnegie Mellon University.

Completed
Registry status
NA
Development phase
1,019
Enrollment target

NCT04133831: Completed NA study, sponsored by Carnegie Mellon University.

NCT04133831 is a NA study that has completed, run by Carnegie Mellon University. The registered enrollment target is 1,019 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04133831, a NA study, has completed, sponsored by Carnegie Mellon University.

COMPLETED
Registry status
NA
Development phase
1,019 participants
Enrollment target

Study Summary

Publicly available outcome assessments for transplant programs do not make salient that some programs tend to reject many of the hearts they are offered, whereas other programs accept a broader range of donor offers. The investigators use empirical studies to test whether transplant center performance data (i.e. transplant and waitlist outcome statistics) that reflect center donor acceptance rates influence laypersons to evaluate centers with high organ decline rates less favorably than centers with low organ decline rates. 1000 lay participants will be recruited from Amazon Mechanical Turk and randomized to one of five different information presentation conditions. Participants will be given an introduction to the donor organ match process, then asked to view the table of transplant outcomes corresponding to the condition they were randomized to. Each participant is asked to choose between two hospitals: one hospital with an non-selective, "accepting" strategy (takes all donor heart offers), and one hospital with a more selective, "cherrypicking" strategy (tends to reject donor offers that are less than "excellent" quality).

Primary Outcome

The outcome variable will be a measure of binary choice between two hospitals: one with a selective donor-heart acceptance strategy and one with a non-selective donor heart acceptance strategy. Participants will respond to the question "Which Hospital is a better choice for patients? Please click on one of the two tables below to indicate which hospital is the better choice." Participants will choose been two outcome tables featuring the selective and non-selective hospital (counterbalanced, su

Interventions

  • OTHER Total Survival
  • OTHER Stratified Transplant Survival

Trial Details

FieldValue
Enrollment Target 1,019 participants
Start Date 2019-11-15
Est. Completion 2020-04-30
Phase NA
Carnegie Mellon University

37 total trials

What the finished NCT04133831 record still lists

NCT04133831 is an interventional study that assigns participants to a tested intervention. Its 1,019 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower).

The record links to 0 conditions, and to 2 interventions - of which Total Survival is the first listed.

NCT04133831 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04133831 about?

NCT04133831 is a clinical study titled "Don't Throw Your Heart Away: Layperson Study 1". Publicly available outcome assessments for transplant programs do not make salient that some programs tend to reject many of the hearts they are offered, whereas other programs accept a broader range of donor offers. The investigators use empirical studies to test whether transplant center performan...

What is the current status of trial NCT04133831?

This trial is currently completed. It is a NA study. The enrollment target is 1,019 participants. The study started on 2019-11-15. Estimated completion is 2020-04-30.

What interventions are being tested in trial NCT04133831?

The interventions under investigation include: Total Survival (OTHER), Stratified Transplant Survival (OTHER).

Who is sponsoring clinical trial NCT04133831?

This trial is sponsored by Carnegie Mellon University, which has 37 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04133831's enrollment target sits among peer trials

1,019 106th of 2000 higher than 1,895 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02178163 · 1,020 participants · NA

    Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

  • NCT05225428 · 1,020 participants · NA

    Video Education With Result Dependent dIsclosure

  • NCT06697600 · 1,020 participants · NA

    A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

  • NCT06760637 · 1,020 participants · Phase 3

    Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04133831, the US trial registry maintained by the National Library of Medicine. NCT04133831 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.